Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17

Wedbush analyst Martin Fan has initiated coverage on Eupraxia Pharmaceuticals (NASDAQ: EPRX) with an Outperform rating. The firm has set a price target of $17 for the company's stock.